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-Lactamases are the main cause of bacterial resistance to penicillins and cephalosporins. Class A -lac-
tamases, the largest group of -lactamases, have been found in many bacterial strains, including mycobacteria,
for which no -lactamase structure has been previously reported. The crystal structure of the class A
-lactamase from Mycobacterium fortuitum (MFO) has been solved at 2.13-Å resolution. The enzyme is a
chromosomally encoded broad-spectrum -lactamase with low specific activity on cefotaxime. Specific features
of the active site of the class A -lactamase from M. fortuitum are consistent with its specificity profile. Arg278
and Ser237 favor cephalosporinase activity and could explain its broad substrate activity. The MFO active site
presents similarities with the CTX-M type extended-spectrum -lactamases but lacks a specific feature of these
enzymes, the VNYN motif (residues 103 to 106), which confers on CTX-M-type extended-spectrum -lacta-
mases a more efficient cefotaximase activity.
Mycobacteria are important causes of infectious diseases.
Although Mycobacterium tuberculosis and Mycobacterium lep-
rae, two slow-growing species, are responsible for the most
serious diseases, some fast-growing species, such as Mycobac-
terium avium, Mycobacterium kansasii, Mycobacterium chelo-
nae, and Mycobacterium fortuitum, may cause opportunistic
infections among AIDS patients (24). In addition, M. fortuitum
has been reported to be responsible for a wide spectrum of
clinical diseases, such as skin or soft tissue infections following
surgery, pulmonary infections, accidental penetrating trauma,
and wounds that come in contact with soil or water contami-
nated with these mycobacteria, though nosocomial infections
are by far the most common (41, 44).
The cell wall of mycobacteria contains mycolic acid, arabi-
nogalactan, and peptidoglycan, forming a covalent complex.
The influx of small hydrophilic agents through the resulting
low-permeability envelope is extremely slow and is thought to
be one of the major factors involved in the resistance of my-
cobacteria to -lactam antibiotics (21, 41). -Lactamase pro-
duction, catalyzing -lactam antibiotic hydrolysis, appears to
be the second mechanism by which mycobacteria express -lac-
tam resistance (9, 21, 35). Chromosomally encoded -lacta-
mases have been detected in most, but not all, mycobacterial
species, including M. fortuitum and M. tuberculosis (43).
The class A -lactamase of M. fortuitum (MFO) is a chro-
mosomally encoded broad-spectrum -lactamase hydrolyzing
both cephalosporins and penicillins. Its substrate profile in-
cludes ureidopenicillins (piperacillin, azlocillin, and mezlocil-
lin), carbenicillin, cephalothin, cefotaxime, and cefuroxime,
but not ceftazidime. Cefoxitin, dicloxacillin, imipenem, and
aztreonam are poorly recognized by the enzyme, and the pro-
tein is inhibited by the penem inhibitor BRL42715 and, to a
lesser extent, clavulanic acid. The specificity profile is similar
overall to those of CTX-M-type enzymes; some TEM-derived
extended-spectrum -lactamases (ESBLs); the chromosomally
encoded ESBLs from Citrobacter sedlakii and Yersinia entero-
colitica; and -lactamases identified in the genera Nocardia,
Kluyvera, and Burkholderia (1, 12, 31, 33, 35, 37). At the amino-
acid level, the mature protein shares 70% identity with the
-lactamase of Mycobacterium smegmatis and between 40 and
45% with the aforementioned proteins. MFO also shares 41%
amino acid identity with the ESBL Toho-1. Many recent stud-
ies have been concerned with the structure solution of TEM,
SHV, or CTX-M-type ESBLs, but few structural data are avail-
able on chromosomally encoded broad-spectrum class A -lac-
tamases. MFO is the first solved structure of a mycobacterial
-lactamase. Its structure-activity relationship was analyzed on
the basis of a comparison between its structure and recently
solved ESBL structures (5, 27, 29, 38).
MATERIALS AND METHODS
Production and crystallization. The gene used for -lactamase expression was
the blaF*-blaF hybrid described by Timm et al. (42). The -lactamase was
produced by M. smegmatis transformed by plasmid piPJ42* in 1 liter of Mu¨ller-
Hinton broth. After centrifugation, the supernatant was collected and concen-
trated on an Amicon 8400. The concentrated solution (130 ml) was dialyzed
against 10 liters of 10 mM Tris-HCl, pH 8. The crude extract was adsorbed on a
High Load Q Sepharose High Performance column (36/10; Pharmacia, Uppsala,
Sweden) preequilibrated with the same buffer. The enzyme was eluted by an
NaCl linear gradient (0 to 0.5 M over 300 ml). The active fractions were pooled
and dialyzed against 25 mM Tris-HCl buffer, pH 6.3. The solution was concen-
trated to 10 ml and further purified by chromatofocusing over the pH range 7 to
4 on a MonoP HR5/20 column (Pharmacia). The active fractions were concen-
trated to 2 ml and filtered through a Superdex 75 10/30 column (Pharmacia) to
eliminate the polybuffer. Crystals of MFO were grown by the vapor diffusion
method under hanging-drop conditions using a protein concentration of 20
mg/ml in 0.1 M Tris HCl buffer, pH 7.3, with polyethylene glycols of different
molecular weights as precipitating agents. Typically, drops containing 5 l of
protein and 5 l of reservoir were allowed to equilibrate at 20°C against a 1-ml
reservoir. Long needles of 150 m by 150 m by 800 m, suited for X-ray
diffraction analysis, were obtained from 27% polyethylene glycol 10000 with
several additives (ethylene glycol, glycerol, methylpentanediol, polyethylene gly-
col 400 at 5% concentration, and 10 mM spermidine).
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Data collection, phase determination, and structure refinement. X-ray diffrac-
tion data were collected on the DW32 synchrotron beamline at the Laboratoire
pour l’Utilization du Rayonnement Electromagne´tique (DCI, Orsay, France)
using a monochromatic radiation of 0.975 Å. The crystal-to-detector (small
MarResearch imaging plate) distance was 180 mm. A total of 45 frames (2°
oscillation per frame and 300-s exposure time) were collected at room temper-
ature. The data were processed with the MOSFLM 5.55 package (23). The
structure was solved by molecular replacement using the program AMoRe (26),
and the model was refined using Refmac5 (4) and Coot (8). Data collection and
refinement statistics are summarized in Table 1.
Protein structure accession number. Atomic coordinates have been deposited
in the Brookhaven Protein Data Bank (PDB) with the accession code 2CC1.
RESULTS
Structure determination. MFO crystallized in space group
P212121 (a  35.66 Å, b  73.42 Å, c  91.32 Å) with one
molecule per asymmetric unit. The structure was solved by
molecular replacement, using as a search model the Strepto-
myces albus G -lactamase structure (referred to hereafter as
SAG; PDB code 1BSG) (6). After refinement, the final crys-
tallographic R factor was 0.17 at 2.13-Å resolution (Table 1).
The unique molecule in the asymmetric unit was well defined
by continuous electron density, except for the N-terminal helix.
Residues 27 to 29 are poorly defined, and breaks appear in the
(2Fo-Fc) map for the side chains of residues 31, 32, 35, 38, and
41. The Ramachandran plot and the secondary-structure anal-
ysis with PROCHECK (22) are consistent with a well-defined
structure. The only residue in a special conformation is Cys69.
This residue lies next to the active-site serine and exhibits this
strained conformation in all known three-dimensional struc-
tures of class A -lactamases. The final structure contains 81
water molecules, mainly in the first coordination shell. Among
water molecules present in the active site, one lies in the
oxyanion hole defined by the backbone nitrogens of Ser70 and
Ser237, and a second is firmly held by Ser70, Glu166, and
Asn170.
Overall structure. The structure of the MFO -lactamase is
similar to those of other class A -lactamases (Fig. 1). The
active site is at the interface between an / domain and an
all- domain. The / domain consists of a five-stranded
-sheet covered by three helices on one side and one helix on
the other. Besides the conserved motifs defining the active site,
the MFO structure shares other well-conserved structural
motifs with other class A -lactamases, suggesting a major role
in the stabilization of the folding of this class of proteins. The
salt bridge between Glu37 and Arg61 is usually well preserved,
like the carboxyl-carboxylate interaction between Asp233 and
Asp246. The absence of a side chain for Gly45 creates a dip in
the -sheet surface in which the benzyl group of Phe66 can fit.
These two residues are strictly conserved among class A -lac-
tamases, and Phe66 has been shown to be essential for protein
folding and function (32). On the other hand, the deletion of
two residues between Ser217 and Ser220 in MFO is a unique
feature among class A -lactamases. This deletion occurs at
the N terminus of a short helix in the upper right corner of the
active site (with the orientation shown in Fig. 2) and reduces it
to a mere single-turn loop. As a consequence of the deletion of
residues 218 and 219, MFO residue 220 is in a standard -helix
conformation, whereas this residue is generally constrained in
other class A -lactamases. In view of this deletion, the ener-
getically unfavorable conformation of residue 220 observed in
all class A -lactamases but MFO is surprising. The backbone
position of the residues surrounding this deletion is displaced
by about 1 Å compared to other class A -lactamases, resulting
in a small backward displacement of strand 3.
Another unique feature of MFO is the occurrence of a
valine in position 167. The Glu166-Val167 bond is in a cis
conformation and is stabilized by a double hydrogen bond
between the backbone of Glu166 and the side chain of Asn136.
In all class A -lactamase structures, residue 167 is in a cis
conformation and is generally a proline.
Active site. The active site of MFO, with its dense hydrogen-
bonding network, is similar to most class A -lactamase active
sites (Fig. 2). The distances between the essential amino acid
side chains are similar to those found in the other class A
-lactamases. Lys73 N is hydrogen bonded to Ser70 O and
Asn132 O1. Similarly, Lys234 N hydrogen bonds to Ser130
O and the carbonyl oxygen of Thr235. The distance between
Lys73 and Glu166 (3.26 Å) is too long for a regular salt bridge.
The relative location of the residues responsible for the cata-
lytic activity (Ser70, Lys73, Ser130, Asn132, Glu166, and
Lys234) is similar to that found in the Toho-1 or TEM-1
enzymes (PDB codes 1IYS and 1XPB) (Fig. 2B and C). Fol-
lowing the KTG motif, residue 237 is a serine. The Ser237
hydroxyl group lies near the active site, as does the guani-
dinium group of Arg278 (Arg278 corresponds to Ambler’s
numbering position 276 because of the insertion of two resi-
dues in positions 274 and 275). These two residues can interact
with the substrate carboxylate. The guanidinium group of
Arg278, located on the C-terminal helix, is directed toward the
active-site cavity and can play a role equivalent to that assigned
to Arg220 in SAG or Arg244 in TEM-1. Its exact location in
the crystal structure is slightly different from that of Toho-1 or
the equivalent groups in SAG and TEM-1, but the flexibility
of the Arg278 side chain is sufficient to allow the superimpo-




Cell dimensions (Å) ..........................a  35.66, b  73.42, c  91.32
Data set
Highest resolution (Å) ......................2.13
Total no. of reflections......................49,318
No. of unique reflections ..................11,576
Completeness (%)
All data ...........................................86.89
Highest shell (Å)............................52.98 (2.185–2.129)
I/	 (I) overall......................................7.86




R free (%) (using 5% of
reflections) ..................................22.3
R.m.s. deviations from ideality
Bond length (Å).............................0.02
Bond angles (°) ..............................1.9
Average B factor (Å2)...................19.0
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sition of its guanidinium group on those found to be equivalent
in Toho-1, SAG, and TEM-1.
The main difference between the MFO and Toho-1 active
sites is the loop 103 to 106 at the entrance of the catalytic cleft.
The sequence in MFO is VPNS, and the backbone conforma-
tion of this segment is similar to that of TEM-1. In contrast, the
sequence VNYN in Toho-1 is typical of CTX-M-type ESBLs,
and an interaction between Asn106 and the backbone nitrogen
of residue 103 induces a different loop conformation.
DISCUSSION
The mechanism by which -lactamases hydrolyze -lactam
antibiotics is known to follow a three-step pathway involving a
Michaelis complex and an acyl-enzyme intermediate. At least
five acylation mechanisms, which could be valuable for MFO,
have been proposed. They are reviewed and studied by molec-
ular dynamics simulation in reference 28. We will focus on
features in or near the active site of MFO that are related to its
substrate specificity.
The structural basis for broad-spectrum activity. As shown
in Table 2, MFO is moderately active on most penicillins and
cephalosporins. The presence of a serine (or threonine) in
position 237 can be related to this broad-spectrum activity. The
Ala237Thr mutation in TEM-1 improves the activity toward
cephalothin and cephalosporin C but decreases that toward
benzylpenicillin and ampicillin (3, 16). Generally, class A -lac-
tamases devoid of a hydroxyl group in position 237 are more
efficient in hydrolyzing penicillins than cephalosporins, while
the presence of a hydroxylated residue gives to the enzyme
rather broad-spectrum characteristics. Comparison of the spe-
cific activities of Klebsiella oxytoca D488 with those of MEN-1
provides a typical example of two enzymes differing mainly by
this hydroxyl group. Lacking this group, K. oxytoca D488 is a
better penicillinase than cephalosporinase, whereas MEN-1 is
rather a broad-spectrum enzyme. Comparable results have
FIG. 1. (Top) Ribbon representation of the class A -lactamase from Mycobacterium fortuitum. The active-site serine (S) is indicated by a black
sphere. (Bottom) Sequence alignment of class A -lactamases from M. fortuitum (accession no. uniprot Q59517), M. tuberculosis H37Rv (P0A516),
S. albus G (P14559), E. coli Toho-1 (Q47066), P. vulgaris K1 (P52664), Y. enterocolitica (Q01166), and E. coli TEM-1 (Q4AE67). The four
conserved motifs of class A -lactamases are boxed. Blue, strictly conserved residues; yellow, active-site conserved residues; green, Arg 220, 244,
or 276 (278); orange, other residues discussed in the text.
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been produced by the Ser237Ala mutation in Proteus vulgaris
(40) or SME-1 (39). The carboxylate of cephalosporins can
more easily hydrogen bond to the Ser237 hydroxyl group than
the carboxylate of penicillins. The insertion of transition state
models of the acylation step generated at the quantum level (7)
into the active site suggests that the hydroxyl group could
hinder the movement of one of the methyl groups of the
penicillin thiazolidine ring during the course of the acylation
process. This can explain the reduction of penicillinase activity
resulting from the introduction of the hydroxyl group, as also
suggested by Toho-1–benzylpenicillin and Toho-1–cephalothin
acyl-enzyme structures (PDB codes 1IYQ and 1IYP) (38).
A second element that can explain the broad substrate pro-
file of MFO is Arg278 (Arg278 corresponds to Ambler’s num-
bering position 276). A specific feature of class A -lactamases
is the guanidinium group of either Arg278, Arg220, or Arg244,
which lies in equivalent positions in the three-dimensional
structures. The removal of the Arg244 side chain by site-di-
rected mutagenesis has been shown to considerably reduce the
enzyme activity against all -lactam substrates in TEM-1 (45).
Similarly, the Arg220Leu mutation in SAG induced a signifi-
cant decrease in the rates of acylation by most classical sub-
strates. Unexpectedly, the mutation of Arg276 to an uncharged
residue in Toho-1 (18) or CTX-M-4 (13) induced only a slight
decrease in kcat/Km on third-generation cephalosporins and no
change for penicillins and first-generation cephalosporins. The
interaction between the substrate carboxylate and the arginine
is somewhat neglected in theoretical calculations because the
docking of -lactam substrates in the active site (at the
Michaelis complex level) leads to interactions of the carboxy-
late with Ser130 and Lys234, and the arginine is remote from
the carboxylate. The arginine, rather than Lys234, is the elec-
trostatic complement of the carboxylate group. If the interac-
tion between Lys234 and the substrate carboxylate is favorable
for recognition and can lead to a decrease in Km, it has to be
removed during acylation and will lead to a similar decrease in
kcat. The most important thing is not the binding energy re-
sulting from the interaction between the substrate carboxylate
and the amine group of the lysine or the guanidinium group of
the arginine but the deformation induced in the -lactam ring
by this interaction. One must consider the efficient part of the
energy that will help to break the scissile -lactam bond. The
interaction between the guanidinium group and the substrate
carboxylate tends to rotate the thiazolidine ring and, together
with the attraction of the carbonyl oxygen in the oxyanion hole
(17), as well as the interaction between the hydroxyl group of
Ser130 and the lone pair of the -lactam nitrogen, results in a
shield stress on the endocyclic amide bond that reduces the
activation barrier. From this point of view, the distance be-
tween the carboxylate and the guanidinium group, as well as
the interaction direction, is an important factor that explains
why the enzyme can discriminate between penicillins and ceph-
alosporins, since the orientations of the carboxylate versus the
-lactam amide bonds are different in the two types of antibi-
otics. An arginine in position 220 or 244 seems more appro-
priate for an increase in the penicillin acylation rate, while
Arg278 seems to only slightly affect third-generation cephalo-
sporin hydrolysis.
Activity against cefotaxime and lack of activity against cef-
tazidime. MFO retains a low specific activity on cefotaxime
(kcat/Km  40 mM

1 s
1) intermediate between the activity
levels of TEM-1 (kcat/Km  1.5 mM

1 s




1) (18). Arg278 and Ser237, favoring
the cephalosporinase activity; the existence in MFO of a larger
FIG. 2. Stereo view of the active site of MFO showing the con-
served motifs of class A -lactamases and other residues discussed in
the text. (A) Oxygen and nitrogen atoms are red and blue, respectively.
Carbon atoms are yellow, green (residues 216 to 220), and cyan (-
loop; residues 166 to 170). The (2Fo-Fc) map is contoured at 1.0 	.
(B) Superimposition of the active sites of MFO (PDB code 2CC1)
(yellow), S. albus G (1BSG) (green), and TEM-1 (1XPB) (red). MFO
residues are labeled in black. SAG Arg220 is labeled in green, and
TEM-1 Arg244 is labeled in red. (C) Superimposition of the active
sites of MFO (yellow) and Toho-1 (red). Residues 166 to 170 are
omitted for clarity.
TABLE 2. Second-order rate constants of MFO, Toho-1, and






Benzylpenicillin 1,000a 3,000c 84,000d
Nitrocefin 4,200a 2,700c 17,000d
Cephaloridine 660a 700c 2,200d
Cephalothin 1,900a 12,000c 650d
Cefotaxime 40b 2,100c 1.5d
Ceftazidime NDb 1.3c 0.07d
Cefoxitin 0.016b 0.00076c 0.006e
Imipenem 0.3b 2.25c 2.0e
a Reference 1.
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pocket between the side chains of residues 104, 167, 170, and
240, allowing better accommodation of the cefotaxime side
chain; and an aspartic acid in position 240 appear to be the
most important factors that can explain the slightly better cef-
otaxime hydrolysis rate of MFO over TEM-1. The Toho-1–
cefotaxime crystal structure shows that Asp240 interacts with
the amino group in the aminothiazole ring of the acylamide
side chain (38). Nevertheless, unlike CTX-M-type ESBLs,
MFO does not seem to be designed for efficient hydrolysis of
cefotaxime. The most prevalent difference between MFO and
CTX-M-type ESBLs that can explain the higher efficiency of
the latter in hydrolyzing cefotaxime is the loop 103-to-106
conformation. In Toho-1, Asn104 interacts with the carbonyl
oxygen of the side chain amide group of the substrate, and
Toho-1 can fix the bulky side chain of cefotaxime more tightly
than MFO.
As for Toho-1 and CTX-M-type ESBLs, ceftazidime is not
recognized by MFO due to sterical hindrance between the
bulky side chain of ceftazidime and the -loop of the protein.
ESBLs have evolved several ways to hydrolyze ceftazidime.
TEM-type ESBLs that can hydrolyze ceftazidime harbor mu-
tations of residues located in or near the -loop that destabi-
lize the -loop and help accommodate the bulky side chain of
ceftazidime. These mutations are generally detrimental to
the hydrolysis of other -lactams. CTX-M-type ESBLs have
evolved differently to gain activity on ceftazidime, privileging
substitutions in strand 3. CTX-M-15, CTX-M-16, and CTX-
M-27 confer eightfold-higher resistance to ceftazidime than
their respective parental enzymes, CTX-M-3, CTX-M-9, and
CTX-M-14, from which they differ by the substitution Asp240Gly
(2). This substitution also decreases the hydrolytic efficiency
against cefotaxime (5). Substitutions in the -loop also arise in
CTX-M-type ESBLs in order to extend their hydrolytic activities
to ceftazidime. CTX-M-19, which is derived from CTX-M-18 by
a Pro167Ser substitution, confers a higher level of resistance to
ceftazidime than cefotaxime (34). None of the characteristics en-
countered in ceftazidime-hydrolyzing ESBLs are found in MFO.
Cefotaxime and ceftazidime have a branched side chain,
with one of the branches identical in both substrates. Crystal-
lographic results show that the common branch, the aminothi-
azole ring, inserts in the active site with sterical hindrance with
Asn170, whereas the other branch protrudes from the active
site, and the extension specific to ceftazidime makes few con-
tacts with the rest of the protein. Substitutions, whether in the
-loop or in the 3-strand, that improve -lactamase activity
on ceftazidime are generally detrimental to the hydrolysis of
other -lactams, because a slight displacement of Glu166 or
Asn170 probably results in the reduction of the deacylation
rate. In the case of ceftazidime, destabilization of the -loop
helps increase the affinity of the enzyme and allows acylation
and deacylation rates, though modest, to be sufficient for sub-
strate hydrolysis. The chromosomal class A -lactamase K1
from Proteus vulgaris, the structure of which is close to that of
MFO, can hydrolyze oxyimino -lactams, such as cefuroxime
or ceftazidime (27). MFO harbors a valine in position 167
instead of the proline in K1, and this small difference between
the -loops of the two enzymes might result in K1 having a
greater activity on ceftazidime than does MFO.
Inhibitors. Arginine 278 seems important in enzyme inacti-
vation by clavulanic acid. The wild-type TEM enzyme appears
to be more sensitive to clavulanic acid than SAG (11) or MFO
(12), and the Arg244Ser mutation in TEM-1 strongly decreases
its sensitivity to the same inactivator (19). It could be tenta-
tively concluded that an arginine in position 220 or 278 (276)
cannot completely compensate for the absence of Arg244 in
the catalysis of the clavulanate moiety rearrangement, which
results in irreversible enzyme inactivation.
Imipenem and cefoxitin act as poor transient inactivators
due to slow hydrolysis and accumulation of the acyl-enzyme.
Since the regions surrounding the SDN loop are similar in
MFO and TEM-1, the interaction between TEM-1 and imi-
penem, investigated by crystallography (PDB code 1BTS) (25),
is probably equivalent for MFO. Because of sterical hindrance
between the Asn132 side chain and the hydroxyethyl group of
imipenem, the acyl-enzyme is trapped in a conformation that
prevents its deacylation. In the imipenem-hydrolyzing class A
-lactamase NMC-A, the position of the Asn132 side chain
enlarges the binding cavity and allows the 6 substituent of
imipenem to fit more easily into the active site. This situation
also prevails for cefoxitin, as the methoxy side chain on the 
face of the -lactam ring is still bulkier than the hydroxyethyl
group of imipenem. In this case, even NMC-A or the SME-1-
related -lactamase is not efficient to hydrolyze this com-
pound. The crystal structure of Bacillus licheniformis BS3 in
complex with cefoxitin (PDB code 1I2W) reveals that the steri-
cal hindrance between the 7-methoxy group of cefoxitin and
Asn132 causes a conformational change of the substrate 7
side chain and eliminates the water molecule needed for
deacylation (10). The mutation Asn132Ala in SAG has been
shown to drastically decrease most -lactam ratios of hydroly-
sis (20), but the removal of the Asn132 side chain would leave
some free space for the methoxy group and allow a better
hydrolysis of cefoxitin. The class A -lactamase of M. tubercu-
losis H37Rv, which shares about 61% similar residues with
MFO, exhibits a glycine in position 132 (15). This enzyme has
a low specific activity on most -lactam antibiotics, but its
ability to hydrolyze cefoxitin is undoubtedly related to the
removal of the Asn132 side chain. Similarly, a glycine residue
occurs at position 132 of the Streptomyces clavuligerus -lacta-
mase. Again, the enzyme exhibits a low specific activity but is
able to hydrolyze cefoxitin (30). The role of Asn132 is not only
to hydrogen bond to the substrate side chain amide group to
correctly position the substrate in the Michaelis complex, but
rather, it is important to tightly fix the substrate in the enzyme
cavity during the course of acylation.
Conclusion. Compared to TEM-1, MFO shows a broadened
and unspecialized spectrum of activity, but MFO did not
evolve from intensive use of cefotaxime in antimicrobial ther-
apy, which rather resulted in CTX-M-type ESBL selection. In
that sense, “broad spectrum” is more suitable to characterize
MFO than “extended spectrum.”
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